BioHarvest Sciences (BHST) Competitors $6.90 +0.08 (+1.17%) As of 12:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock BHST vs. MREO, RGNX, ORKA, LIMN, RAPP, PRTC, TRML, PGEN, FULC, and ARCTShould you be buying BioHarvest Sciences stock or one of its competitors? The main competitors of BioHarvest Sciences include Mereo BioPharma Group (MREO), REGENXBIO (RGNX), Oruka Therapeutics (ORKA), Liminatus Pharma (LIMN), Rapport Therapeutics (RAPP), PureTech Health (PRTC), Tourmaline Bio (TRML), Precigen (PGEN), Fulcrum Therapeutics (FULC), and Arcturus Therapeutics (ARCT). These companies are all part of the "pharmaceutical products" industry. BioHarvest Sciences vs. Its Competitors Mereo BioPharma Group REGENXBIO Oruka Therapeutics Liminatus Pharma Rapport Therapeutics PureTech Health Tourmaline Bio Precigen Fulcrum Therapeutics Arcturus Therapeutics BioHarvest Sciences (NASDAQ:BHST) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation. Which has more volatility & risk, BHST or MREO? BioHarvest Sciences has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, Mereo BioPharma Group has a beta of 0.46, indicating that its share price is 54% less volatile than the S&P 500. Which has preferable earnings and valuation, BHST or MREO? BioHarvest Sciences has higher revenue and earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than BioHarvest Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioHarvest Sciences$25.19M4.50-$12.91M-$0.50-13.80Mereo BioPharma Group$10M45.71-$43.25M-$0.07-41.07 Do analysts recommend BHST or MREO? BioHarvest Sciences currently has a consensus target price of $13.67, suggesting a potential upside of 98.07%. Mereo BioPharma Group has a consensus target price of $7.60, suggesting a potential upside of 164.35%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts clearly believe Mereo BioPharma Group is more favorable than BioHarvest Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioHarvest Sciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Does the media prefer BHST or MREO? In the previous week, BioHarvest Sciences had 1 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 2 mentions for BioHarvest Sciences and 1 mentions for Mereo BioPharma Group. BioHarvest Sciences' average media sentiment score of 0.78 beat Mereo BioPharma Group's score of 0.00 indicating that BioHarvest Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioHarvest Sciences 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mereo BioPharma Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BHST or MREO more profitable? Mereo BioPharma Group has a net margin of 0.00% compared to BioHarvest Sciences' net margin of -31.30%. Mereo BioPharma Group's return on equity of -69.33% beat BioHarvest Sciences' return on equity.Company Net Margins Return on Equity Return on Assets BioHarvest Sciences-31.30% -307.04% -33.21% Mereo BioPharma Group N/A -69.33%-57.27% Do institutionals & insiders have more ownership in BHST or MREO? 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 5.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. SummaryMereo BioPharma Group beats BioHarvest Sciences on 10 of the 17 factors compared between the two stocks. Get BioHarvest Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for BHST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BHST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BHST vs. The Competition Export to ExcelMetricBioHarvest SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$113.30M$2.89B$5.49B$9.01BDividend YieldN/A2.64%5.39%4.09%P/E Ratio-13.8021.5627.4320.06Price / Sales4.50281.29398.25108.31Price / CashN/A41.4736.1356.90Price / Book86.257.518.085.67Net Income-$12.91M-$55.05M$3.16B$248.47M7 Day Performance1.47%3.16%2.12%2.90%1 Month Performance4.07%5.92%4.43%5.75%1 Year PerformanceN/A5.82%35.62%21.36% BioHarvest Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BHSTBioHarvest SciencesN/A$6.90+1.2%$13.67+98.1%N/A$113.30M$25.19M-13.80N/ANews CoverageMREOMereo BioPharma Group1.9449 of 5 stars$2.66-5.0%$7.60+185.7%-16.8%$445.20M$10M0.0040RGNXREGENXBIO4.415 of 5 stars$8.39-4.1%$31.63+276.9%-19.8%$438.90M$83.33M0.00370ORKAOruka Therapeutics2.219 of 5 stars$11.08-4.7%$40.38+264.4%N/A$435.43MN/A0.00N/AHigh Trading VolumeLIMNLiminatus PharmaN/A$9.48-42.9%N/AN/A$431.84MN/A0.00N/AGap UpRAPPRapport Therapeutics1.9466 of 5 stars$11.43-3.2%$32.67+185.8%-52.8%$431.04MN/A0.00N/ANews CoverageGap UpHigh Trading VolumePRTCPureTech Health2.6077 of 5 stars$17.15-4.4%$45.00+162.4%-27.6%$430.90M$4.83M0.00100Gap UpHigh Trading VolumeTRMLTourmaline Bio2.1447 of 5 stars$16.54-1.0%$49.33+198.3%+29.0%$429.20MN/A0.0044PGENPrecigen3.7317 of 5 stars$1.42-0.7%$6.00+322.5%+8.1%$422.11M$3.92M0.00190News CoverageHigh Trading VolumeFULCFulcrum Therapeutics0.3442 of 5 stars$7.10-3.8%$6.29-11.5%+13.6%$398.37M$80M0.00100ARCTArcturus Therapeutics3.7851 of 5 stars$13.33-7.5%$53.50+301.4%-36.6%$390.81M$152.31M0.00180News CoverageAnalyst ForecastHigh Trading Volume Related Companies and Tools Related Companies Mereo BioPharma Group Competitors REGENXBIO Competitors Oruka Therapeutics Competitors Liminatus Pharma Competitors Rapport Therapeutics Competitors PureTech Health Competitors Tourmaline Bio Competitors Precigen Competitors Fulcrum Therapeutics Competitors Arcturus Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BHST) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioHarvest Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioHarvest Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BHST Stock Alerts